Hyderabad: Covaxin has been found safely, well tolerated and immunogenic in children, with neutralizing antibodies found averaging 1.7 times higher than in adults.
It has come in the data produced by Phase II and III pediatric studies in children aged 2 to 18 and uploaded in Prefrint Server Medrxiv on Thursday by vaccine developers, Bharat Biotech.
With this, Covaxin has been the only Covid-19 vaccine in the world to study and produce data from trials in children as young as two years.
The test results showed seroconversion at 95-98% in children of all age groups, four weeks after they received their second dose.
This shows the response of superior antibodies in children compared to adults, said Bharat Biotech.
The researchers said that there were no serious side effects reported in the trial.
Of the 526 volunteers who participated in the trial, 374 children reported mild or moderate symptoms with 78.6% completed in one day, the research said.